Contribution of Hepatic and Intestinal Lipoproteins to Human Atherosclerosis
Withdrawn
- Conditions
- Heart Disease
- Registration Number
- NCT01321476
- Lead Sponsor
- Piedmont Healthcare
- Brief Summary
This study will use excess tissue from endoscopic or surgical procedures to examine the elements of plaque that are found in the carotid walls of patients who have a type of heart and blood vessel disease called atherosclerosis. Tissue will be collected from patients undergoing carotid procedures as well as patients undergoing liver and/or intestinal biopsies. This lab study will examine the different types of proteins that play a role in developing heart plaque.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Age ≥18 years
- Scheduled for a clinically indicated, standard-of-care carotid endarterectomy (CEA) OR scheduled for a clinically indicated, standard-of- care surgical, laparoscopic or endoscopic intestinal biopsy or excision OR scheduled for a clinically indicated, standard-of-care surgical, laparoscopic or endoscopic liver biopsy or partial resection/excision
- Ability and willingness to consent and Authorization for use of PHI
Exclusion Criteria
- Age ≤18 years
- Inability or unwillingness to consent and Authorization for use of PHI
- FOR CAROTID PATIENTS - history of carotid trauma, that is determined by the Principal Investigator to significantly have changed the carotid tissue structure
- FOR CAROTID PATIENTS - history of middle- or large-vessel vasculitis, that is determined by the Principal Investigator to significantly have changed the carotid tissue structure
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Demonstrated Plaques up to 30 months Presence of both liver and intestinally derived lipoprotein particles demonstrated in human atherosclerotic plaques.
- Secondary Outcome Measures
Name Time Method